openPR Logo
Press release

Chronic Inducible Urticaria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Celldex Therapeutics, Jasper Therapeutics

01-13-2025 02:31 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Chronic Inducible Urticaria Pipeline Insights 2024

Chronic Inducible Urticaria Pipeline Insights 2024

Chronic Inducible Urticaria Pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Inducible Urticaria treatment therapies, analyzes DelveInsight.

Chronic Inducible Urticaria Overview:

Chronic Inducible Urticaria (CIndU) is a type of chronic urticaria where hives or wheals are triggered by specific physical or environmental factors, such as pressure, temperature changes, sunlight, or exercise. Unlike chronic spontaneous urticaria, which occurs without clear external triggers, CIndU symptoms are linked to identifiable stimuli. This condition can severely affect quality of life, requiring a comprehensive treatment approach.

CIndU's pathophysiology involves an overreaction of mast cells, which release histamine and other inflammatory mediators in response to triggers, causing symptoms like itching, redness, and swelling. Treatment typically includes antihistamines, leukotriene receptor antagonists, and, in severe cases, immunomodulatory agents.

Management focuses on avoiding known triggers and providing symptom relief, with patient education playing a critical role. Ongoing research is improving understanding and treatment, offering hope for better control of this condition.

Request for a detailed insights report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Chronic Inducible Urticaria Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Inducible Urticaria Therapeutics Market.

Key Takeaways from the Chronic Inducible Urticaria Pipeline Report

DelveInsight's Chronic Inducible Urticaria pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Inducible Urticaria treatment.
In October 2024, Jasper Therapeutics reported preliminary results from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adults with cold urticaria (ColdU) or symptomatic dermographism (SD), two common subtypes of CIndU. Of the 15 participants enrolled, 14 (93%) showed a clinical response within 6 weeks. In the 120mg dose group, 10 out of 12 participants (83%) achieved a complete response, and 1 participant had a partial response. Briquilimab was well tolerated, with no serious adverse events or grade 3 or higher adverse events reported. Jasper has received regulatory approval to enroll a 180mg dose cohort in the study and plans to present full data in the first half of 2025.
In September 2024, Evommune announced the enrollment of the first patient in a Phase II trial of EVO756 for adults with CIndU.
In June 2024, Celldex Therapeutics revealed data showing that barzolvolimab significantly improves angioedema at 12 weeks in its Phase II clinical trial for chronic spontaneous urticaria (CSU).
In May 2024, Novartis shared new data confirming the long-term efficacy and safety of remibrutinib, a selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU).
In March 2024, Jasper Therapeutics announced that the first patient had been dosed in its Phase Ib/IIa (SPOTLIGHT) clinical study of subcutaneous briquilimab for treating CIndU.
In February 2024, ARS Pharmaceuticals reported positive efficacy results from its Phase II inpatient chronic spontaneous urticaria study using neffy (epinephrine nasal spray), an investigational new drug.
Key Chronic Inducible Urticaria companies such as Celldex Therapeutics, Jasper Therapeutics, and others are evaluating new drugs for Chronic Inducible Urticaria to improve the treatment landscape.
Promising Chronic Inducible Urticaria pipeline therapies in various stages of development include Barzolvolimab, and others.

Chronic Inducible Urticaria Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Chronic Inducible Urticaria Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inducible Urticaria treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inducible Urticaria market.

Download our free sample page report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Emerging Drugs

Barzolvolimab: Celldex Therapeutics

Chronic Inducible Urticaria Companies

There are about four key companies developing therapies for Chronic Inducible Urticaria. Among them, Celldex Therapeutics has drug candidates for Chronic Inducible Urticaria in the most advanced stage, specifically Phase II.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Inducible Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic Inducible Urticaria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Inducible Urticaria Therapies and Key Companies: Chronic Inducible Urticaria Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Pipeline Therapeutic Assessment
• Chronic Inducible Urticaria Assessment by Product Type
• Chronic Inducible Urticaria By Stage
• Chronic Inducible Urticaria Assessment by Route of Administration
• Chronic Inducible Urticaria Assessment by Molecule Type

Download Chronic Inducible Urticaria Sample report to know in detail about the Chronic Inducible Urticaria treatment market @ Chronic Inducible Urticaria Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Chronic Inducible Urticaria Current Treatment Patterns
4. Chronic Inducible Urticaria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Inducible Urticaria Late-Stage Products (Phase-III)
7. Chronic Inducible Urticaria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Inducible Urticaria Discontinued Products
13. Chronic Inducible Urticaria Product Profiles
14. Chronic Inducible Urticaria Key Companies
15. Chronic Inducible Urticaria Key Products
16. Dormant and Discontinued Products
17. Chronic Inducible Urticaria Unmet Needs
18. Chronic Inducible Urticaria Future Perspectives
19. Chronic Inducible Urticaria Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Inducible Urticaria Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Inducible Urticaria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Celldex Therapeutics, Jasper Therapeutics here

News-ID: 3812826 • Views:

More Releases from DelveInsight Business Research LLP

Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead S
Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Lates …
DelveInsight's "Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Crohn's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn's Disease Market Forecast @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some
Complicated Urinary Tract Infections Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLi
Complicated Urinary Tract Infections Market Report 2034: Epidemiology Data, Pipe …
DelveInsight's "Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Complicated Urinary Tract Infections, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Complicated Urinary Tract Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Myasthenia Gravis Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexio
Myasthenia Gravis Market Report 2034: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast @ https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some of the
Gastroesophageal Reflux Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno
Gastroesophageal Reflux Disease Market Report 2034: Epidemiology Data, Pipeline …
DelveInsight's "Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease

All 5 Releases


More Releases for Chronic

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market Res …
Latest industry research report on: Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them
11-10-2016 | Health & Medicine
MRR.biz
Global Chronic, Acute, And Neuropathic Pain Market: Opioids To Remain Most Value …
The research report, titled “Frontier Pharma: Chronic, Acute And Neuropathic Pain - GPCR And Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes,” analyzes the historical as well as the existing performance of this market, emphasizing specifically on various types of therapies applied to treat chronic, acute, and neuropathic pain. According to this 68-page study, the worldwide market for chronic, acute, and neuropathic pain has been observing a significant
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system. Pain is an important protection system of the human body. But when it becomes chronic, as it frequently